378 related articles for article (PubMed ID: 31354733)
21. Expression of Tim-3/Galectin-9 pathway and CD8+T cells and related factors in patients with cystic echinococcosis.
Zhao H; Ma Y; Tian F; Li B; Xiao N; Mo X; Aibibula M; Min H; Cai X; Zhang T; Ma X
Exp Parasitol; 2023 Nov; 254():108623. PubMed ID: 37793539
[TBL] [Abstract][Full Text] [Related]
22. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma.
Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
J Dermatol Sci; 2019 Dec; 96(3):134-142. PubMed ID: 31787505
[TBL] [Abstract][Full Text] [Related]
23. Interaction between Galectin-9/TIM-3 pathway and follicular helper CD4
Zhuo Y; Zhang YF; Wu HJ; Qin L; Wang YP; Liu AM; Wang XH
Biomed Pharmacother; 2017 Oct; 94():386-393. PubMed ID: 28772217
[TBL] [Abstract][Full Text] [Related]
24. Activated Tim-3/Galectin-9 participated in the development of multiple myeloma by negatively regulating CD4 T cells.
Zhang R; Chen S; Luo T; Guo S; Qu J
Hematology; 2024 Dec; 29(1):2288481. PubMed ID: 38108336
[TBL] [Abstract][Full Text] [Related]
25. Galectin-9 Alleviates LPS-Induced Preeclampsia-Like Impairment in Rats via Switching Decidual Macrophage Polarization to M2 Subtype.
Li ZH; Wang LL; Liu H; Muyayalo KP; Huang XB; Mor G; Liao AH
Front Immunol; 2018; 9():3142. PubMed ID: 30687334
[TBL] [Abstract][Full Text] [Related]
26. T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins.
Schlichtner S; Yasinska IM; Lall GS; Berger SM; Ruggiero S; Cholewa D; Aliu N; Gibbs BF; Fasler-Kan E; Sumbayev VV
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36599470
[TBL] [Abstract][Full Text] [Related]
27. Activation of Tim-3-Galectin-9 pathway improves survival of fully allogeneic skin grafts.
Wang F; He W; Yuan J; Wu K; Zhou H; Zhang W; Chen ZK
Transpl Immunol; 2008 Apr; 19(1):12-9. PubMed ID: 18346632
[TBL] [Abstract][Full Text] [Related]
28. The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis.
Ju Y; Shang X; Liu Z; Zhang J; Li Y; Shen Y; Liu Y; Liu C; Liu B; Xu L; Wang Y; Zhang B; Zou J
Mol Immunol; 2014 Mar; 58(1):85-91. PubMed ID: 24333756
[TBL] [Abstract][Full Text] [Related]
29. Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells.
Wang F; Wan L; Zhang C; Zheng X; Li J; Chen ZK
Immunobiology; 2009; 214(5):342-9. PubMed ID: 19362679
[TBL] [Abstract][Full Text] [Related]
30. The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy.
Yang R; Hung MC
Sci China Life Sci; 2017 Oct; 60(10):1058-1064. PubMed ID: 29027155
[TBL] [Abstract][Full Text] [Related]
31. Tim-3/Galectin-9 signaling pathway is involved in the cytokine changes in mice with alveolar echinococcosis.
Li S; Zhu Y; Wang S; Li Y; Pang N; An M; Zhang F; Ding J
Mol Biol Rep; 2022 Aug; 49(8):7497-7506. PubMed ID: 35715604
[TBL] [Abstract][Full Text] [Related]
32. Lipopolysaccharide mediates time-dependent macrophage M1/M2 polarization through the Tim-3/Galectin-9 signalling pathway.
Zhang W; Zhang Y; He Y; Wang X; Fang Q
Exp Cell Res; 2019 Mar; 376(2):124-132. PubMed ID: 30763585
[TBL] [Abstract][Full Text] [Related]
33. Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) and TIM-3 ligands in peripheral blood from patients with systemic lupus erythematosus.
Jiao Q; Qian Q; Zhao Z; Fang F; Hu X; An J; Wu J; Liu C
Arch Dermatol Res; 2016 Oct; 308(8):553-61. PubMed ID: 27394439
[TBL] [Abstract][Full Text] [Related]
34. The immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 autocrine loop in human myeloid leukemia cells.
Gonçalves Silva I; Rüegg L; Gibbs BF; Bardelli M; Fruehwirth A; Varani L; Berger SM; Fasler-Kan E; Sumbayev VV
Oncoimmunology; 2016 Jul; 5(7):e1195535. PubMed ID: 27622049
[TBL] [Abstract][Full Text] [Related]
35. Galectin-9 in cancer therapy.
Fujihara S; Mori H; Kobara H; Rafiq K; Niki T; Hirashima M; Masaki T
Recent Pat Endocr Metab Immune Drug Discov; 2013 May; 7(2):130-7. PubMed ID: 23514536
[TBL] [Abstract][Full Text] [Related]
36. Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways.
Vega-Carrascal I; Reeves EP; Niki T; Arikawa T; McNally P; O'Neill SJ; Hirashima M; McElvaney NG
J Immunol; 2011 Mar; 186(5):2897-909. PubMed ID: 21263071
[TBL] [Abstract][Full Text] [Related]
37. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells.
Dardalhon V; Anderson AC; Karman J; Apetoh L; Chandwaskar R; Lee DH; Cornejo M; Nishi N; Yamauchi A; Quintana FJ; Sobel RA; Hirashima M; Kuchroo VK
J Immunol; 2010 Aug; 185(3):1383-92. PubMed ID: 20574007
[TBL] [Abstract][Full Text] [Related]
38. Galectin-9: A Suppressor of Atherosclerosis?
Yu J; Zhu R; Yu K; Wang Y; Ding Y; Zhong Y; Zeng Q
Front Immunol; 2020; 11():604265. PubMed ID: 33250901
[TBL] [Abstract][Full Text] [Related]
39. Tim-3 Is Upregulated in NK Cells during Early Pregnancy and Inhibits NK Cytotoxicity toward Trophoblast in Galectin-9 Dependent Pathway.
Sun J; Yang M; Ban Y; Gao W; Song B; Wang Y; Zhang Y; Shao Q; Kong B; Qu X
PLoS One; 2016; 11(1):e0147186. PubMed ID: 26789128
[TBL] [Abstract][Full Text] [Related]
40. Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity.
André S; Kojima S; Yamazaki N; Fink C; Kaltner H; Kayser K; Gabius HJ
J Cancer Res Clin Oncol; 1999; 125(8-9):461-74. PubMed ID: 10480338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
